Tandem and Eli Lilly carried out trials to demonstrate the advantages of using Lyumjev in combination with Control-IQ ...

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that ...

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received clearance for the use of rapid-acting insulin with its ...

The Federal Trade Commission (FTC) has filed a legal complaint accusing the 3 largest pharmacy benefit managers (PBMs) in the ...

A new class of insulin taken once a week could be just as effective for managing blood sugar in people with type 1 and type 2 ...

Findings from two US trials of efsitora, developed by pharma company Eli Lilly, have been presented at the annual meeting of ...

An investigational once-weekly insulin was noninferior to a daily option for patients with type 2 diabetes, but proved risky ...

Insulin Lispro. The first rapidly acting analogue developed was approved for clinical use in 1996. It is obtained by inverting of the lysine at position 28 and the proline at position 29 on the ß ...

All patients were given the drugs in combination with insulin lispro, which was taken at meal times. At week 26, the mean glycated haemoglobin level (HbA1c) – a measure of how much glucose is ...

New research published in The Lancet and presented at this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) in ...

Participants also used insulin lispro for meals. The mean A1c decreased from 7.88% at baseline to 7.41% at week 26 with efsitora and from 7.94% to 7.36% with degludec, with a nonsignificant ...